DES	SIGNAT	TTAL LETTER TO THE UTED/ELECTED OFFICE (ING A FILING UNDER 3	DO/EO/US)	Attorney's Docket Number   040750-5002-US			
CO.	NCERI	ING A FILING CHULK S	0.0.0.0.7				
	ernation	al Application. No.	International Filing Date 4 August 1999				
Titl	e of Inv	ention: IDENTIFICATION PROTEIN KINA		ACTERIZATION OF A NOVEL RIBOSOMAL S6			
Apı	olicant F	For DO/EO/US: LUDWIG	INSTITUTE FOR CANCER RES	EARCH			
Nex	t Busine	t timely submits this patent a ess Day Rule (MPEP § 710.0 ) the following items and oth	<ol><li>Applicant herewith submits to</li></ol>	n is extended until Monday, February 5, 2001 under the othe United States Designated/Elected Office			
1.	[X]	This is a FIRST submission	on of items concerning a filing und	ler 35 U.S.C. 371.			
2.	į	This is a SECOND or SUI	BSEQUENT submission of items	concerning a filing under 35 U.S.C. 371.			
3.	[]	This express request to be	gin national examination procedu	res (35 U.S.C. 371(f)) at any time rather than delay			
	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claim						
	[X]		mational Preliminary Examinatio	il was made by the 19th month from the carriest elamed			
	[X]	priority date.	al Application as filed (35 U.S.C.	371(c)(2))			
m	[A]	a. [] is transn	nitted herewith (required only if n	ot transmitted by the International Bureau).			
Tu		b. [] has been transmitted by the International Bureau.					
Ĩ.		c. [X] is not required, as the application was filed in the United States Receiving Office (RO/US).					
6.	[]	A translation of the International Application into English (35 U.S.C. 371(c)(2)).					
疝	[X]	Amendments to the claim	s of the International Application	under PCT Article 19 (35 U.S.C. 371(c)(3)).			
a				not transmitted by the International Bureau).			
		b. [ ] have be	en transmitted by the Internationa	l Bureau.			
U		c. [ ] have no	t been made; however, the time li	mit for making such amendments has NOT expired.			
N		d. [X] have not been made and will not be made.					
8॒		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9	[]	An oath or declaration of the inventors (35 U.S.C. 371(c)(4)).					
<u>tu</u> .	[]	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Ite	me 11 ta	o 14 helow concern other d	locument(s) or information inclu	ided:			
	[]	An Information Disclosur	e Statement under 37 CFR 1.97 a	nd 1.98.			
12.		An assignment document for recording. A separate cover sheet in compliance with					
	. ,	37 CFR 3.28 and 3.31 is i					
13.	[]	A FIRST preliminary ame	endment.	· .			
	įį	A SECOND or SUBSEQ	UENT preliminary amendment.				
14.	[X]	Other items or informatio		•			
		a. [X]	WIPO Publication - (98 pages)	•			
		b. [X]	PCT/IB/304				
		c. []	PCT/IB/308				
		d. [X]	PCT/IB/332	anno Liating			
:		e. [X]	Statement Accompanying Sequence Listing (paper copy and	ad diskette)			
		f. [X]	Request to transfer CRF of sequ				
		g. []	PCT/ISA/210	once maning			
		h. [X] i. [X]	PCT/ISA/210 PCT/ISA/220				
			PCT/IPEA/408				
		J. [ ] k. [ <b>X</b> ]	PCT/IPEA/409				

**ATTORNEY DOCKET NUMBER** 

U.S. APPLICATION NO.

Not You ossile ment 622	.58 PCT/US99/17595	040750-5002-	US			
15. [X] The follow	ving fees are submitted:					
	ional Fee (37 CFR 1.492(a)(1)-(5)	):				
Search Report has be						
	Search Report has been prepared by the EPO or JPO \$860.00  International preliminary examination fee paid to					
USPTO (3	İ					
No international preli						
USPTO (3						
paid to US	j					
Neither international	İ					
(37 CFR 1	j					
(37 CFR 1	j					
International prelimit	(37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00 International preliminary examination fee paid to USPTO					
(37 CFR 1	j					
of PCT Ar	of PCT Article 33(2)-(4) \$100.00					
	\$860.00					
Surcharge of \$130.00 for f						
[ ] <b>20</b> [ ] <b>30</b> months from						
(37 CFR 1.492(e)).		180	\$			
Claims	Number Filed Number		_			
Total Claims	41 - 20 = 21	X \$ 18.00  \$ 378.00	_			
Independent Claims	17 - 3 = 14	X \$ 80.00  \$1,120.00   + \$270.00  \$ 270.00	_			
<u> Multiple dependent claim(</u>	_					
TO	_					
	\$2,628.00					
Processing fee of \$130.00						
from the earliest claimed p	+\$					
	duction by ½ for filing by small entity. All entities associated with this plication presently fully meet the requirements of 36 CFR §1.9(d).					
application presently fully	- \$1,314.00					
		TOTAL NATIONAL FEE =	\$1,314.00			
	1	TI.	,			
	sed assignment (37 CFR 1.21(h)).					
	panied by an appropriate cover she	et				
(37 CFR 3.28, 3.31).	\$40.00 per property	TOTAL PERCENCLOSED	+\$			
		TOTAL FEES ENCLOSED =	\$1,314.00			
		Amount to be	10			
		<u>refunded</u>	\$  \$			
· · · · · · · · · · · · · · · · · · ·		charged	<u> </u> φ			

INTERNATIONAL APPLICATION NO.

a. [X] A check in the amount of \$1,314.00 to cover the above fees is enclosed.

b. [ ] Please charge my Deposit Account No. 50-0310 in the amount of \$.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. [X] Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 CFR §1.16 and §1.17 which may be required, or credit any overpayment to Deposit Account No. 50-0310.

Customer No. 009629 SEND ALL CORRESPONDENCE TO: Morgan, Lewis & Bockius LLP 1800 M Street, N.W. Washington, D.C. 20036 (202) 467-7000

Thomas F. Poché Reg. No. 45,017

Submitted: February 5, 2001

## JC05 Rec'd PCT/PTO

0 5 FEB 2001

Attorney Docket No. 40750-5002-US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ivan GOUT et al.	)
Application No.: Unassigned (based on PCT/US99/17595)	) Group Art Unit: Unassigned )
Filed: February 5, 2001	) Examiner: Unassigned
For: IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF A NOVEL	) ) )
RIBOSOMAL S6 PROTEIN KINASE	)

Commissioner for Patents Washington, D.C. 20231 **BOX SEQUENCE** 

## STATEMENT ACCOMPANYING SEQUENCE LISTING

Dear Sir:

The undersigned hereby states upon information and belief that the Sequence Listing submitted concurrently herewith does not include matter which goes beyond the content of the application as filed and that the information recorded on the diskette submitted concurrently herewith is identical to the written Sequence Listing submitted herewith.

Respectfully submitted,

Dated: February 5, 2001

MORGAN, LEWIS & BOCKIUS LLP

Ву:\_\_\_\_\_

Thomas F. Poché

Registration No. 45,017

MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036

Tel: 202-467-7000

Fax: 202-467-7176